PROSTest, a Multigene Liquid Biopsy Signature, Effectively Stratifies Patients With High PSA for Prostate Biopsy

PROSTest demonstrates improved stratification value relative to PSA and could significantly reduce PSA-driven false positive biopsies. Out of 259 non-PCa subjects biopsied based on high PSA levels, applying PROSTest could potentially eliminate 227 biopsies (87.6%). PROSTest superior NPV was not confounded as a tradeoff for the PPV as PROSTest exhibited a sensitivity of ~95% (675/711 PCa detected).